After all day moving positively, Grifols shares give one more push in mid -afternoon and shoot 12.5% in Ibex 35 to mark 10.82 euros after the first announcements of its capital Markets Day:
The Financial Director of Grifols, Rahul Srinivasan, has indicated that the Hemodervados Company will restore the remuneration to its shareholders from 2025 and that sees margin for shares. “We expect a radical change in profitability for the shareholder,” he said in the framework of the Capital Markets Day held in London.
Grifols plans to register revenues of around 7,700 million euros in 2025 -existing the Law on Reduction of American Inflation -, which represents an ascent close to 7% compared to the billing recorded in 2024, when it marked a historical record when it was located at 7,212 million euros, a 10.3% higher than the one accounted for in 2023.
Within the framework of its ‘Strategic Plan 2025-2029’, with a ten-year vision the Catalan company has advanced that its forecasts also pass through Enter about 10,000 million euros in 2029 and approach 14,000 million euros in 2034. The estimated income for 2029 and 2034 would be 38.6% and 94.1% higher than that registered in 2024, respectively, while it should be noted that the company has included the impact of the US inflation reduction law (IRA).
In its ‘Guidance’ for this year, without counting on the US standard, Grifols hopes to register a gross exploitation result (Ebitda) that is around 2,025 million euros, raising by 14% the 1,779 million euros obtained between January and December 2024.
By 2029, the Hemodevados firm hopes to register an adjusted Ebitda of about 2.9 billion euros in 2029, which would mean a 63% rise compared to that obtained at the end of the year 2024.
Regarding the annual accounts of 2024, the CEO of Grifols, Nacho Abia, has shown a “strong” confidence about what the firm can achieve in the coming years, since Grifols has fulfilled its expectations. Specifically, one of the objectives of the Catalan company, considered by Abia, one of the three main world actors with a “clear” competitive advantage in the plasma sector, goes through executing its value creation plan to increase the profitability of the shareholders. “
The company reached in 2024 a net profit of 157 million euros, which means raising it 271% compared to those achieved in 2023, thanks above all to the substantial improvement of its income, which exceed 7,212 million euros and rise to double digit compared to the previous year, 10.3%.